Difference between revisions of "Part:BBa K3904403"
Bernadeta A (Talk | contribs) |
Bernadeta A (Talk | contribs) |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
− | + | <partinfo>BBa_K3904403 short</partinfo> | |
Line 7: | Line 7: | ||
[[File:T--Vilnius-Lithuania--amebyeLogo dark.png|right|100px|AmeBye]] | [[File:T--Vilnius-Lithuania--amebyeLogo dark.png|right|100px|AmeBye]] | ||
− | Vilnius-Lithuania iGEM 2021 project [https://2021.igem.org/Team:Vilnius-Lithuania <b>AmeBye</b>]looks at amebiasis holistically and comprehensively, | + | Vilnius-Lithuania iGEM 2021 project [https://2021.igem.org/Team:Vilnius-Lithuania <b>AmeBye</b>]looks at amebiasis holistically and comprehensively, therefore target <i>E. histolytica</i> from several angles: prevention and diagnostics. Our team's preventive solution consists of probiotics engineered to produce naringenin - an antiprotozoal compound. Two strains of genetically modified microorganisms were chosen as the main chassis - world-renowned <i>Lactobacillus casei</i> BL23 (<i>Lactobacillus paracasei</i>) and <i>Escherichia coli</i> Nissle 1917. Furthermore, the team made specific gene deletions to enhance naringenin production and adapted a novel toxin-antitoxin system to prevent GMO spreads into the environment. The diagnostic part includes a rapid, point of care, user-friendly diagnostic test identifying extraintestinal amebiasis. The main components of this test are aptamers specific to the <i>E. histolytica</i> secreted proteins. These single-stranded DNA sequences fold into tertiary structures for particular fit with target proteins. |
__TOC__ | __TOC__ | ||
Line 13: | Line 13: | ||
=Usage and Biology= | =Usage and Biology= | ||
− | CRISPR-Cas9 is a versatile genome-editing technique. In our approach to editing <i>E. coli</i> Nissle 1917 genome, we have used two plasmid based system enabling to combine of Lambda Red recombination and CRISPR-Cas9 as counterselection tools | + | CRISPR-Cas9 is a versatile genome-editing technique. In our approach to editing <i>E. coli</i> Nissle 1917 genome, we have used two plasmid based system enabling to combine of Lambda Red recombination and CRISPR-Cas9 as counterselection tools encoded in [https://www.addgene.org/62225/ pCas] and [https://www.addgene.org/62226/ pTarget]. |
==Mechanism of genome editing== | ==Mechanism of genome editing== | ||
Line 19: | Line 19: | ||
pCas plasmid is used for Cas9, Lambda Red system expression, and plasmid curing of pTarget. Cas9 - the RNA-guided endonuclease - is expressed constitutively, while the expression of Lambda Red genes (Gam, Exo, Beta) is under the control of arabinose inducible promoter araBp. pTarget plasmid caries constitutively expressed single-guide RNA (sgRNA). This RNA molecule, as and in nature, is composed of two central parts: CRISPR RNA (crRNA) and tracrRNA. crRNA is 17-20 nt length RNA sequence complementary to the targeted DNA adjacent to the protospacer adjacent motif (PAM) and tracrRNA is the scaffold for the Cas (in this case Cas9) nuclease binding to guide RNA and forming the ribonucleoprotein complex (1). In nature those two parts exist as two separate RNA molecules, however, in laboratory experiments they are usually combined into one single-guide RNA (sgRNA). As both pCas and pTarget plasmids are in a cell, Cas9 nuclease and sgRNA are able to form ribonucleoprotein complex and perform a double-strand break in the chosen part of the DNA. However, if arabinose has been added to the cell culture and a double-stranded DNA repair template is present in the cell, the Lambda Red system performs homologous recombination. If this process is unsuccessful, the Cas9-sgRNA complex will cause a double-strand break and will cause cell death (2). This is employed as a counterselection in order to avoid the additional antibiotic as selection marker usage. | pCas plasmid is used for Cas9, Lambda Red system expression, and plasmid curing of pTarget. Cas9 - the RNA-guided endonuclease - is expressed constitutively, while the expression of Lambda Red genes (Gam, Exo, Beta) is under the control of arabinose inducible promoter araBp. pTarget plasmid caries constitutively expressed single-guide RNA (sgRNA). This RNA molecule, as and in nature, is composed of two central parts: CRISPR RNA (crRNA) and tracrRNA. crRNA is 17-20 nt length RNA sequence complementary to the targeted DNA adjacent to the protospacer adjacent motif (PAM) and tracrRNA is the scaffold for the Cas (in this case Cas9) nuclease binding to guide RNA and forming the ribonucleoprotein complex (1). In nature those two parts exist as two separate RNA molecules, however, in laboratory experiments they are usually combined into one single-guide RNA (sgRNA). As both pCas and pTarget plasmids are in a cell, Cas9 nuclease and sgRNA are able to form ribonucleoprotein complex and perform a double-strand break in the chosen part of the DNA. However, if arabinose has been added to the cell culture and a double-stranded DNA repair template is present in the cell, the Lambda Red system performs homologous recombination. If this process is unsuccessful, the Cas9-sgRNA complex will cause a double-strand break and will cause cell death (2). This is employed as a counterselection in order to avoid the additional antibiotic as selection marker usage. | ||
− | ==<i>adhE</i> gene knockout== | + | ==<i>adhE</i> gene knockout importance to AmeBye project== |
This 20 nt length RNA sequence is designed to target acetaldehyde dehydrogenase (adhE) gene. Knockout of <i>adhE</i> gene disrupts the conversion of acetyl-CoA to ethanol in the cell, therefore more acetyl-CoA can be converted to malonyl-CoA (3). | This 20 nt length RNA sequence is designed to target acetaldehyde dehydrogenase (adhE) gene. Knockout of <i>adhE</i> gene disrupts the conversion of acetyl-CoA to ethanol in the cell, therefore more acetyl-CoA can be converted to malonyl-CoA (3). | ||
− | |||
− | |||
Malonyl-CoA is used by chalcone synthase during the production of naringenin chalcone, which is later converted to naringenin (3). | Malonyl-CoA is used by chalcone synthase during the production of naringenin chalcone, which is later converted to naringenin (3). | ||
+ | |||
+ | |||
+ | ==Genome editing efficiency== | ||
+ | |||
+ | In our experiments <i>adhE</i> gene has not been knocked out. The particular reason is unknown but the most convenient explanation is that sgRNA binding site in the genome is not complementary to our designed sgRNA seed sequence. | ||
+ | |||
<!-- --> | <!-- --> |
Revision as of 21:16, 21 October 2021
adhE-specific sgRNA
Introduction
Vilnius-Lithuania iGEM 2021 project AmeByelooks at amebiasis holistically and comprehensively, therefore target E. histolytica from several angles: prevention and diagnostics. Our team's preventive solution consists of probiotics engineered to produce naringenin - an antiprotozoal compound. Two strains of genetically modified microorganisms were chosen as the main chassis - world-renowned Lactobacillus casei BL23 (Lactobacillus paracasei) and Escherichia coli Nissle 1917. Furthermore, the team made specific gene deletions to enhance naringenin production and adapted a novel toxin-antitoxin system to prevent GMO spreads into the environment. The diagnostic part includes a rapid, point of care, user-friendly diagnostic test identifying extraintestinal amebiasis. The main components of this test are aptamers specific to the E. histolytica secreted proteins. These single-stranded DNA sequences fold into tertiary structures for particular fit with target proteins.
Contents
Usage and Biology
CRISPR-Cas9 is a versatile genome-editing technique. In our approach to editing E. coli Nissle 1917 genome, we have used two plasmid based system enabling to combine of Lambda Red recombination and CRISPR-Cas9 as counterselection tools encoded in pCas and pTarget.
Mechanism of genome editing
pCas plasmid is used for Cas9, Lambda Red system expression, and plasmid curing of pTarget. Cas9 - the RNA-guided endonuclease - is expressed constitutively, while the expression of Lambda Red genes (Gam, Exo, Beta) is under the control of arabinose inducible promoter araBp. pTarget plasmid caries constitutively expressed single-guide RNA (sgRNA). This RNA molecule, as and in nature, is composed of two central parts: CRISPR RNA (crRNA) and tracrRNA. crRNA is 17-20 nt length RNA sequence complementary to the targeted DNA adjacent to the protospacer adjacent motif (PAM) and tracrRNA is the scaffold for the Cas (in this case Cas9) nuclease binding to guide RNA and forming the ribonucleoprotein complex (1). In nature those two parts exist as two separate RNA molecules, however, in laboratory experiments they are usually combined into one single-guide RNA (sgRNA). As both pCas and pTarget plasmids are in a cell, Cas9 nuclease and sgRNA are able to form ribonucleoprotein complex and perform a double-strand break in the chosen part of the DNA. However, if arabinose has been added to the cell culture and a double-stranded DNA repair template is present in the cell, the Lambda Red system performs homologous recombination. If this process is unsuccessful, the Cas9-sgRNA complex will cause a double-strand break and will cause cell death (2). This is employed as a counterselection in order to avoid the additional antibiotic as selection marker usage.
adhE gene knockout importance to AmeBye project
This 20 nt length RNA sequence is designed to target acetaldehyde dehydrogenase (adhE) gene. Knockout of adhE gene disrupts the conversion of acetyl-CoA to ethanol in the cell, therefore more acetyl-CoA can be converted to malonyl-CoA (3).
Malonyl-CoA is used by chalcone synthase during the production of naringenin chalcone, which is later converted to naringenin (3).
Genome editing efficiency
In our experiments adhE gene has not been knocked out. The particular reason is unknown but the most convenient explanation is that sgRNA binding site in the genome is not complementary to our designed sgRNA seed sequence.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 9
- 1000COMPATIBLE WITH RFC[1000]
References
- Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213).
- Jiang, Y., Chen, B., Duan, C., Sun, B., Yang, J., & Yang, S. (2015). Multigene editing in the Escherichia coli genome via the CRISPR-Cas9 system. Applied and environmental microbiology, 81(7), 2506-2514.
- Wu, J., Du, G., Chen, J., & Zhou, J. (2015). Enhancing flavonoid production by systematically tuning the central metabolic pathways based on a CRISPR interference system in Escherichia coli. Scientific reports, 5(1), 1-14.